Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Aerosolized pharmaceutical composition with low potential toxicity, significantly reducing airway inflammation and remodelling More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
This project is based on several experimental findings that identify a Bcl-2 family protein as important for mast cell survival in allergic reactions. Inhibition of this protein leads to a decreased number of mast cells in inflamed tissue More
Adjuvant that induces a potent antigen-specific CD8 cytotoxic T-cell response with long lasting immunity More
Two types of vaccines for preventing and treating allergic diseases including atopic dermatitis, allergic asthma, allergic rhinitis, allergic conjunctivitis, and urticaria. More
The University of Edinburgh has developed a new method of screening for polymorphs and solvates of drug compounds that has potential to revolutionise the way polymorph screening is conducted. More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Allergic rhinitis (hay fever)
- Allergies (other)
- Allergy, ophthalmic
- Allergy, skin
- Anaphylaxis
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us